We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxonica | OXN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.125 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.125 | 3.125 |
| Top Posts |
|---|
Posted at 18/2/2008 16:53 by escondido last post today -Item from Proactive Investor - sorry if posted already - 'Oxonica soars on commercial validation of Envirox Monday, February 18, 2008, 12:22 PM Shares in Oxonica ( AIM: OXN ), the nanomaterials group, more than doubled after the company said it received "further validation of its Envirox fuel borne catalyst". The catalyst is used by Stagecoach Group plc, which confirmed that it had delivered fuel savings of more than 5% across the Company's 7000 strong UK bus fleet. Adrian Havlin, Stagecoach Group Technical Engineer said: "Our vehicles have driven more than 700 million miles on Envirox, and to achieve a consistent result across a diverse fleet over 3 years testifies to the robustness of the technology. We are particularly pleased with the performance of the product both in ultra low sulphur diesel and in blends containing biodiesel, which are now in widespread use across our fleet." Oxonica added that it had also recently completed trials in Italy and Germany which also returned positive results, and it had entered into distribution deals for Envirox in Germany and Russia that were already generates sales. Kevin Matthews, CEO, said: "The evidence for the performance of Envirox is becoming increasingly compelling at a time when the issues of climate change and high fuel costs are becoming acute. This proven technology offers the potential to make a real difference to carbon dioxide emissions today. In the UK, reducing diesel fuel use by 5% will save 3 million tonnes of carbon dioxide per year, and Envirox can achieve this while, at the same time, reducing the burden of high fuel costs on the transport sector." Hopefully get a mention in the press tomorrow good luck all holders esc |
Posted at 25/11/2007 14:48 by mbugger Some sort of knak by M.M.s-they know all the tricks,never tell the punter[investor]unti |
Posted at 29/9/2007 08:56 by ariane Take AIM: Dragon's Den helps Oxonica turn Turkey Published: 17:21 Friday 28 September 2007 By Douglas Bence, Companies Correspondent Nanomaterials group Oxonica is involved with improving fuel combustion, providing ultra violet screening in sun care products and tagging objects used in security identification. For those that may not know, nano is a Latin word meaning small, in a modern sense a one thousand millionth part. It was being small, if not nano-sized that gave AIM-listed Oxonica the biggest problem in its history earlier this year, forcing its shares to be suspended and triggering a hunt for new capital. One of its best known products is Envirox, a fuel catalyst that improves consumption and reduces emissions. It was tested by transport group Stagecoach in London before it sold that part of its bus operations to the Australian group Macquarie. Oxonica's energy division had a contract with Petrol Ofisi, Turkey's leading oil company. Most of Turkey's fuel comes from Russia and tends to have a high, and environmentally undesirable, sulphur content that was hitting Petrol Ofisi's market share. It was thought that these disadvantages could be reduced by Envirox. Tests were done and the benefits measured. But for a science-based company like Oxonica, which spun out of Oxford University in 1999, there were too many variables: different vehicles on sometimes dubious road surfaces with different drivers in a range of environments and weather conditions. Although there was plenty of positive anecdotal evidence, Petrol Ofisi felt it insufficiently hard for it to promote the treated fuel as aggressively as planned. The results were dismissed as inconclusive and Oxonica fired. The size of the deal and the initial uncertainties associated with its loss gave the board no option but to suspend the shares at 117.5p on 27 April. They had been pushed up to 150p when the Petrol Ofisi contract was landed in August 2006 and on 24 October peaked at 172.5p. Oxonica clarified its position with Petrol Ofisi, tried to rebuild the trial programme and took drastic steps to reduce costs. But when the share suspension was lifted on 5 June, Oxonica's shares plunged to 34p and bottomed on 15 June at 30.5p. 'We did all the things you would expect as well as initiating a detailed strategic review of the business the conclusion of which was to raise additional funds,' chief executive Kevin Matthews told Citywire. Although the discussions are now at an advanced stage to raise a currently undisclosed amount, but probably around £7 million, the story changes at this point. Oxonica came to AIM in July 2005 with a private placing targeting individuals rather than City institutions. The second largest shareholder with 16% is entrepreneur Richard Farleigh, a former potential investor in the reality TV programme Dragon's Den. He has become chairman of Oxonica and is masterminding the fundraising, again with individuals. It is hoped that this will increase liquidity in the stock, which closed today 2p higher 36.5p with just 13 deals involving under 28,000 shares, and attract institutional interest. Revenue in the six months to 30 June increased 142% to £3.1 million against £1.3 million last time. But £2.1 million of this against £300,000 comprised sales of Envirox to Petrol Ofisi. Excluding these, Envirox revenue was slightly lower than in the first half of 2006 mainly due to the loss of the Stagecoach London depots following the sale to Macquarie. As well as selling to the energy industry, Oxonica also deals with the healthcare, materials and security markets. The security business has a number of orders for delivery in the second half and a research and development agreement has been reached with the US company BD for diagnostic work. Optisol is an ultra violet protection system designed for use in sunscreen creams and products to treat premature aging. Sales doubled to £265,000 in the half year against £108,000 last time. The product is now used in 27 formulations by 14 customers including Boots in nine countries. Although gross profit increased 59% to £1.2 million against £800,000, the operating loss for the first half was £3.2 million against £2.9 million. Citywire Verdict: Definitely a company to watch, and a share worth acquiring for the medium to long term. |
Posted at 21/6/2007 15:13 by initiate Well they issued this at 13:44 - what a strange coincidence that it shot up 80% yesterday - someone must be psychic !Oxonica plc 21 June 2007 21st June 2007 Oxonica plc Receipt of milestone purchase orders for Security Business and Strategy Update Oxonica plc announces the receipt of a series of purchase orders totalling US $1.16 million for a number of development products to be delivered over the next 9 months as part of a project with one of the existing customers of Oxonica's security business. In addition to the above amount, further purchase orders worth US $525k are contingent on the achievement of intermediate technical milestones. These orders represent significant progress in moving Oxonica's security technology towards product development on a commercial scale. These orders follow on from orders placed by the same customer through the period from November 2005 to April 2007 with a total value to date of US $1.52 million. Oxonica Security develops covert brand and product security solutions based on proprietary, patented nanomaterials. The addressable market for this anti-counterfeiting technology is estimated at US $440 million and comprises applications in high value documents, tax stamps, pharmaceuticals, fuel and luxury goods. Strategy Update As previously announced on 6 June 2007, the Directors are undertaking a detailed review of the overall strategy of the Group and its funding requirements. This review is now nearing a conclusion and the Board anticipates being able to update investors shortly. The Directors believe this will require the Company to raise additional funds through an equity offering. |
Posted at 08/3/2007 07:40 by hyper al demankoIt says it in back and white, but no timeline is mentioned. I remember Proteome Sciences (PRM) had a agreement with a US company and investors waited for some 2 years only to be told that trials had failed because of lack understanding by the user! BD Site |
Posted at 15/10/2006 08:27 by grupo guitarlumber MIDAS SHARE TIPS Oxonica: small but perfectly formed 8 October 2006 Say 'nanotechnology' and many of us would go scurrying for a dictionary. A few would recognise the term as referring to the technology of extremely smallscale materials or mechanisms. For investors it means a small but fascinating opportunity. Nanotechnology is more than science fiction. It is a reality and the paramount example on the London stock market is Oxonica. A spin-off from Oxford University, Aim-listed Oxonica may not be a household name, but there is a good chance that you have one of its products on your bathroom shelf without even knowing it. If you have ever bought Boots' Soltan or Tesco's Finest sun creams, you are an indirect customer of Oxonica, which provides its Optisol product to both companies. Optisol is a nanotechnology product, a highly complex material built up molecule by molecule-that acts as a defence against UVA radiation - sunlight that does not actually burn you red, but which nevertheless is a cause of skin cancer. Popular knowledge of sun screens centres on the SPF level, but this refers only to UVB protection. Growing awareness of the dangers of UVA is expected to increase demand for products like Optisol. Another application for Oxonica's products is fuel efficiency. Envirox is a complex molecule which, when added in minute quantities to diesel, cuts carbon emissions and it makes the fuel more efficient. In August, Envirox was adopted by Petrol Efisi, the leading oil company in Turkey. From now on, lorry drivers in Turkey will get more miles per gallon and pollute less. British bus company Stagecoach has also adopted the fuel additive. It is thought that large oil groups are looking at Envirox. Should a company like Shell or BP adopt Envirox, the boost to Oxonica would be dramatic. But even without this, the group is on the path to success. The Efisi deal is expected to create sales of about £8 million a year, a massive jump for a company whose turnover last year was only £1.28 million. The deal also means that it will report its first profit for the second half of 2006. Oxonica has several other products up its sleeve, but these two alone indicate this is not just another speculative technology company but a business with real commercial potential. Among those who agree is Richard Farleigh, the millionaire private-investor best known as one of the BBC's Dragons' Den panel, who has a 17 per cent stake. Midas verdict: Oxonica is not cheap. Its shares had been sliding until the Efisi deal sparked a jump. They are now 140p and earnings are forecast to hit just 1p a share in 2007. But what Oxonica has going for it are proven products at the start of their commercial life. |
Posted at 24/9/2006 15:32 by s_merryfield OxonicaWarren Buffet famously said he would not invest in companies he did not understand. For that reason, investors who do not have a doctorate in nanotechnology might take the Sage of Omaha's advice and give , which commercialises materials made up of minute particles, a wide berth. The company was spun-out of the University of Oxford in 1999 in order to turn wizzy nanotechnology ideas into commercial success stories. Seven years and millions of pounds of losses later, analysts believe Oxonica will finally turn a profit by the end of the year. Oxonica had two pieces of good luck. First, softly spoken Dragon's Den guru Richard Farleigh took an early interest, beginning with an initial £300,000 investment at the time Oxonica was spun-out of Oxford, rising to £5m. Secondly, in 2001, former academic Dr Kevin Matthews was hired to sharpen up Oxonica's act and make it more palatable to the business community. Oxonica's chief executive does have a doctorate from Oxford and so can easily understand what the company does, but he also left academia early in his career to cut his teeth in the private sector. As a result, Oxonica got the required commercial focus it needed. Mr Farleigh took an enormous punt and made a handsome return, something Questor does not begrudge him given the risk he took, but the question new investors must ask today is what upside remains? The answer is: potentially an awful lot. Certainly enough to warrant a punt, particularly as the risk has reduced significantly since Mr Farleigh first entered the fray. Oxonica's major commercial breakthrough came in August when it announced a deal to supply Turkish oil company Petrol Ofisi with its new green technology, Envirox. Already used by Stagecoach, Envirox is added to diesel and boosts fuel efficiency by 5pc to 11pc, while reducing carbon dioxide emissions. Ten other oil companies are believed to be studying the technology. If it proves successful, Oxonica will have broken into what Panmure Gordon analyst Mark Davis estimates might be a £1bn market. Another Oxonica success, Opitsol, is added to sun creams to increase the length of time they protect skin from ultra-violet rays. Boots started using it in its Soltan cream in 2005 and is already coming back for more. Risks remain: the company is small, with a market value of £54m, and relies on cutting edge technologies, but even Buffet must admit there is clear commercial potential in what Oxonica is doing. At a recent price of 130p, Oxonica's shares are a buy. Source: |
Posted at 28/3/2006 22:18 by elfman I agree current pe is very high but this reflects potential for growth. The money/intellect has developed the products and so long as they are not too ambitious with their future developements then they should not need a further rights issue. IF the money spent on promoting the current products gets reasonable results then it should not be difficult to increase turnover form £1.2 million. If not and they continue to spend then no doubt the share price will suffer. Nanoplex technologies took £1:70 per share. They will be more in the know regarding potential and they took a deal above current share price so they must be fairly optimistic of future. Stagecoach were impressed enough with envirox to take 10% of the company and IMO they wouldn't have done this if they didn't believe in the future earnings from this product alone. Boots have often been market leaders in skin care and have been impressed enough with optisol to put it in their main sun creams. All in all some impressive deals to date. I agree that investors in this company are looking forward, however this is a company in a sector that will expand rapidly IMO. |
Posted at 15/3/2006 08:23 by elfman Never known a share to be so static.Good positive comment from yesterdays RNS. "Nanotechnology is a fast growing, fledgling industry," said Dr Kevin Matthews, Oxonica's CEO. "It is therefore very reassuring for our customers and investors to know that Oxonica has rigorous quality control procedures in place meeting the globally recognised and respected ISO9001 standards at all stages from consultation through research and development to final products." |
Posted at 28/9/2005 09:54 by grupo guitarlumber Interim ResultsRNS Number:8495R Oxonica plc 28 September 2005 28 September 2005 Oxonica plc Maiden interim results for the six months ended 30 June 2005 Oxonica plc (LSE: OXN.L), one of Europe's leading nanomaterials groups, today announces maiden interim results for the 6 months ended 30 June 2005. Improved financial performance Highlights * Turnover up six fold on prior year period at #684,000 (H104: #93,000) * Successful completion of the roll-out of the group's fuel borne nanocatalyst, Envirox(TM), across Stagecoach Group plc's UK and New Zealand bus depots * Successful in-store launch of UV protection additive, Optisol(TM), which was incorporated into Boots' Soltan range of premium sun defence facial creams - sales exceeded expectations * Biodiagnostics technology development continues to make progress in line with planned milestones * Completed #2.6 million rights issue and employee fundraising (net of expenses) in February 2005 * Completed #7.1 million placing (net of expenses) and shares admitted to trading on AIM on 20 July 2005 Commenting on today's announcement, Dr Kevin Matthews, Chief Executive, said: "Following the successful placing and admission of the Oxonica's shares on AIM in July, we are delighted to be announcing our maiden interim results as a listed company. The improved financial performance over the period highlights the commercial strength and attraction of our leading nanotechnology products to our international blue chip customers and partners. We remain focused on developing groundbreaking nanotechnology solutions to address international markets and we are well positioned to leverage our growing reputation for providing customers with innovative commercial applications." For further information, please contact: Oxonica plc 01865 856 700 Kevin Matthews, Chief Executive Richard Clarke, Finance Director Sonia Bouzid, PR Manager Smithfield Consultants 020 7360 4900 Sara Musgrave George Hudson Notes to editors Oxonica is one of Europe's leading nanomaterials groups, with products already launched into international markets. The company was spun-out from the University of Oxford in 1999 and is based in Oxford, England. Oxonica currently employs 37 professional staff and is led by a strong and commercially experienced management team. Oxonica's mission is to focus on the development of innovative commercial solutions for international markets using its expertise in the design and application of nanomaterials. It owns a diverse portfolio of demand driven products that offer substantial benefits to the target markets of environmental, healthcare and materials. Lead products include: * Envirox(TM) Fuel Borne Nanocatalyst - a nanocatalyst improving fuel economy and reducing emissions * Optisol(TM) UV Absorber - a revolutionary photostable UV protection system designed to optimise the performance of quality sunscreens and anti-premature aging products Oxonica is also active in searching for the next generation of products and is already engaged in developing transformational detection technologies which will enable a new generation of ultrasensitive multiplex diagnostic tools for the clinical diagnostic and life science markets. In addition, the company is developing other UV absorber technologies into polymer systems and coatings, based on similar technologies to that used in Optisol(TM). Oxonica completed a #2.6 million rights issue and employee fundraising (net of expenses) in February 2005. It then completed a #7.1 million placing (net of expenses) and its ordinary shares were admitted to trading on AIM on 20 July 2005. The admission to AIM has raised additional capital for the Group's development, improved its profile internationally with customers and suppliers and has assisted in the recruitment, retention and incentivisation of employees. Chairman's statement Introduction Oxonica has continued to make significant progress in the first half of 2005 with the commercial adoption by lead customers of its two principal products, Envirox(TM) fuel borne nanocatalyst and Optisol(TM) UV absorber. The period saw the successful completion of the roll-out of Envirox(TM) across Stagecoach Group's bus depots in the UK and New Zealand. In April 2005, Boots launched the first range of its premium Soltan sunscreen products incorporating Optisol(TM). Sales have been encouraging, resulting in additional orders during the period. Oxonica completed a rights issue and employee fundraising in February 2005, which raised #2.6 million. The Company also successfully completed a #7.1 million fundraising, net of costs and expenses and the Company's shares were admitted to trading on AIM on 20 July 2005. Results In the six months ended 30 June 2005, turnover was #684,000 an increase of 635% compared with the same period last year. This does not include the income received under the DTI SMART grant for the biodiagnostics programme of #79,000 (2004: #115,000). Development, sales and marketing and administration costs increased by 31% to #2,320,000 as Oxonica continued to increase its commercial efforts in respect of Envirox(TM) and Optisol(TM). The operating loss increased by 17% to #1,866,000 and the cash outflow before financing was up 16% at #2,644,000 (2004: #2,273,000). Business overview Oxonica Energy: The principal achievement during the period was the successful completion of the roll-out of Envirox(TM) across the Stagecoach bus depots in the UK and New Zealand. The newly established operational and technical support teams at Oxonica Energy ensured that no significant operational issues arose during the roll-out. After the period end, a contract was signed for a trial with a second major UK bus company and depots are now being selected for the trial. In March 2005, Envirox(TM) was incorporated into a premium branded diesel fuel which has been launched in retail forecourts in the Philippines. Following the initial launch, a review is now underway with our local distributor to establish the level of promotional support that will be required in the Philippines going forward and to evaluate the potential return on this investment. Sales of Envirox(TM) for trials in Singapore and Australia were made during the period and these trials are continuing to plan. Shortly after the period end, Oxonica Energy sold Envirox(TM) for trials in India to a major local group which has now been appointed as the Company's exclusive distributor for the country. Discussions regarding trials are continuing with major oil and mining companies. In order to sell Envirox(TM) into the US for on-highway use, a US Environmental Protection Agency ("EPA") approval is required. A submission to EPA was made in April 2005 and the initial 12 month evaluation period is currently underway. Oxonica Healthcare: In April 2005, Optisol(TM) was successfully launched in store by Boots in their own brand premium Soltan facial sunscreen range. Sales have exceeded expectations, resulting in repeat orders for Optisol(TM) and Boots are currently evaluating the potential to use Optisol(TM) more widely across their product range. A number of other major cosmetics companies are now in the final stages of evaluation and are looking to incorporate Optisol(TM) into certain of their product ranges for the 2006 summer season. The biodiagnostics technology development, which is supported by a DTI SMART grant, has continued to make significant technical progress in line with planned milestones. Oxonica Materials: Technical development work is continuing in connection with the application of the UV protection technology to polymers, plastics and coatings. Initial commercial activity has commenced with regard to identifying suitable strategic partners with whom to take this technology forward. Regulatory: Oxonica continues to work with regulatory bodies and other stakeholders to develop an appropriate regulatory framework for nanotechnology. Future outlook The overall outlook for the Group remains optimistic, particularly in view of the increasing fuel cost burden on the transport industry. Specifically, Oxonica has now demonstrated with Stagecoach and Boots that it has the operational capability to supply and support its customers through successful product roll- outs. The continued high level of trials activity is encouraging although resource constraints have resulted in a longer conversion process for Envirox(TM) trials, particularly in Asia. The listing on AIM, together with the associated fund raising, represents significant progress for the Group. Oxonica is currently strengthening its UK and Asia Pacific sales and business development operations in order to more effectively support trials of Envirox(TM) and increase the rate of commercialisation. The Board looks to the future with confidence as it continues to concentrate on developing commercial applications from nanotechnology materials. CM Moore Chairman Consolidated profit and loss account For the period ended 30 June 2005 Six months Six months Year to to 30 June to 30 June 31 December 2005 2004 2004 Unaudited Unaudited Audited #'000 #'000 #'000 Turnover 684 93 391 Cost of Sales (309) (39) (109) -------------------- Gross profit 375 54 282 Development, Sales and marketing and administration costs (2,320) (1,766) (3,664) Other operating income 79 115 175 -------------------- Operating profit/(loss) (1,866) (1,597) (3,207) Interest receivable 21 41 63 Interest payable (105) (78) (148) -------------------- Profit/(loss) on ordinary activities (1,950) (1,634) (3,292) Tax credit on loss on ordinary activities - - 131 -------------------- Loss on ordinary activities after taxation and retained for the period (1,950) (1,634) (3,161) -------------------- Basic loss per share (0.09)p (0.42)p (0.81)p Fully diluted loss per share (0.08)p (0.41)p (0.80)p ==================== Consolidated balance sheet As at 30 June 2005 30 June 30 June 31 December 2005 2004 2004 Unaudited Unaudited Audited #'000 #'000 #'000 Fixed assets Intangible Fixed Assets 185 210 198 Tangible Fixed Assets 661 421 568 -------------------- 846 631 766 Current assets Stocks 233 145 159 Debtors 991 423 502 Cash at bank and in hand 498 1,644 600 -------------------- 1,722 2,212 1,261 Creditors:amounts falling due in less than one year (1,269) (688) (1,320) -------------------- Net current assets/(liabilities) 453 1,524 (59) -------------------- Total assets less current liabilities 1,299 2,155 707 Creditors:amounts falling due after more than one year (2,437) (2,403) (2,481) -------------------- Net liabilities (1,138) (248) (1,774) ==================== Capital and reserves Equity share capital 3 1 1 Share premium account 10,210 7,626 7,626 Profit and loss account (11,351) (7,875) (9,401) -------------------- Shareholders' funds (1,138) (248) (1,774) ==================== Consolidated cashflow statement For the period ended 30 June 2005 Six months Six months Year to to 30 June to 30 June 31 December 2005 2004 2004 Unaudited Unaudited Audited #'000 #'000 #'000 Operating loss (1,866) (1,597) (3,207) Depreciation and amortisation 96 102 223 (Increase) in stocks (73) (16) (30) (Increase) in Debtors (489) (197) (254) (Decrease) in Creditors (52) (315) (77) -------------------- Net cash outflow from operating activities (2,384) (2,023) (3,345) -------------------- Returns on investments and servicing of finance Interest received 21 41 63 Interest paid (105) (78) (148) -------------------- Net cash flow from returns on investment and servicing of finance (84) (37) (85) -------------------- Taxation R&D Tax credit - - 109 -------------------- Capital expenditure Purchase of tangible fixed assets (176) (213) (470) -------------------- Net cash flow from capital expenditure and financial investment (176) (213) (470) -------------------- -------------------- Cash outflow before financing (2,644) (2,273) (3,791) -------------------- Financing activities Proceeds of share issues 2,587 3,926 3,926 Repayment of medium and long term loans (6) (2) 237 Increase/(Decr ease) in finance leases (39) (40) 195 -------------------- Net cash inflow/(outflo w) from financing 2,542 3,884 4,358 -------------------- -------------------- Increase/(decr ease) in cash in the period (102) 1,611 567 ==================== Notes to the interim report For the period ended 30 June 2005 1. Basis of preparation The financial information contained in this interim report does not constitute statutory accounts as defined on section 240 of the Companies Act 1985. The interim financial information is unaudited. The financial information for the year ended 31 December 2004 has been extracted from the statutory accounts of Oxonica Materials Limited for that period, on which the auditors issued an unqualified opinion. The financial information has been prepared using the same accounting policies as the audited accounts of Oxonica Materials Limited for the year ended 31 December 2004. The interim report for the six months ended 30 June 2005 was approved by the Board on 27 September 2005. Copies of this statement are being sent to all shareholders and will be available to the public at the Company's registered office at 7 Begbroke Science Park, Sandy Lane, Yarnton, Kidlington, Oxfordshire, OX5 1PF. 2. Ultimate parent company On 16 June 2005 the issued share capital of Oxonica Materials Limited was acquired by Oxonica plc, by means of a share for share exchange and Oxonica plc became the ultimate holding company for the members of the Oxonica group of companies. In order to facilitate understanding of the accounts they have been prepared on the basis that Oxonica plc was the ultimate holding company for the Group with effect from 1 January 2005. The comparative figures for the period to 30 June 2004 and for the year ended 31 December 2004 are those for Oxonica Materials Limited (formerly Oxonica Limited) which was the ultimate holding company for the Group for those periods. 3. Share Capital Prior to the acquisition of Oxonica Materials Limited by Oxonica plc, on 11 February 2005 Oxonica Materials Limited reorganised its share capital. A rights issue and employee fundraising occurred, raising #2.6 million and this resulted in total ordinary share capital after the reorganisation and fundraising of #3,303 issued at a nominal value of #0.01. 4. Earnings per share The loss per ordinary share is calculated by reference to the loss attributable to ordinary shareholders divided by the weighted average number of shares in issue during each period as follows: 30 June 30 June 31 December 2005 2004 2004 Unaudited Unaudited Audited #'000 #'000 #'000 Loss for the period (1,950) (1,634) (3,161) ------------------- --------- --------- --------- Basic weighted average 21,078,929 3,881,700 3,881,700 number of shares Basic loss per share (0.09)p (0.42)p (0.81)p ------------------- --------- --------- --------- Fully diluted weighted average number of 24,281,223 3,952,684 3,952,684 shares Fully diluted loss per share (0.08)p (0.41)p (0.80)p On 16 June 2005, at the same time as the share for share exchange, Oxonica plc completed a 75 for 1 bonus issue of shares which increased the number of ordinary shares in issue from 330,319 to 25,104,244. For the purpose of the earnings per share calculation, the comparative figures have been adjusted to reflect the impact of the bonus issue. 5. Post balance sheet events On 5 July 2005, Stagecoach Bus Holdings Limited elected to exercise their first option in accordance with the option agreements dated 22 September 2004 and 5 July 2005. Under this option, 991,644 ordinary shares with a nominal value of #0.01 were issued by the Company. On 20 July 2005, the shares in Oxonica plc were admitted to trading on AIM. On admission to AIM the shareholder loans in Oxonica Materials Limited were converted into ordinary shares in Oxonica plc or repaid in cash, dependent upon the discretion of the shareholder who made the loan. The total converted into equity was #1,964,518 with the remaining balance of #235,414 being repaid in cash. Also on admission to AIM the Company completed a placing, raising #8.3 million in exchange for issuing ordinary shares at a nominal value of #0.01 to both existing and new investors. The total ordinary share capital after the placing and admission to AIM was #368,053.29 issued at a nominal value of #0.01. This information is provided by RNS The company news service from the London Stock Exchange END IR BIGDCLUDGGUR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
